The struggle is real for Endo. The Dublin-headquartered firm continues to see a drop in financial performance as its generic and injectable products fail to capture the market.
Endo reported a 10% decrease in total net revenues in Q4 2023, making a total of $498m compared to $556m in the same period last year
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?